Mesoblast Gets FDA Approval For New Potency Assay, Stock Up In Pre-Market

rttnews.com · 2026-09-24

Thursday, Mesoblast Limited (MESO) announced that the United States Food and Drug Administration has approved the implementation of a new potency assay, T-cell Proliferation Inhibition BioAssay, for release and stability monitoring of all new commercial product lots of its FDA-approved mesenchymal stromal cell product Ryoncil.

Read the full story at rttnews.com →